var data={"title":"Ceftazidime: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ceftazidime: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5845?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ceftazidime-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ceftazidime: Patient drug information&quot;</a> and <a href=\"topic.htm?path=ceftazidime-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ceftazidime: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147933\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Fortaz;</li>\n      <li>Fortaz in D5W;</li>\n      <li>Tazicef</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147934\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ceftazidime For Injection;</li>\n      <li>Fortaz</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147980\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Cephalosporin (Third Generation)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147937\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cystic fibrosis:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer&rsquo;s labeling:</i> 90 to 150 mg/kg/day every 8 hours (maximum: 6 g daily)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternative recommendations:</i> Intermittent IV infusion: 200 to 400 mg/kg/day divided every 6 to 8 hours (maximum: 8 to 12 g daily); <b>or</b> by continuous IV infusion: 100 to 200 mg/kg/day (maximum: 12 g daily) (Zobell, 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Empiric therapy in immunocompromised patients:</b> IV: 2 g every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endophthalmitis, bacterial (off-label use):</b> Intravitreal: 2 to 2.25 mg/0.1 mL NS in combination with vancomycin (Jackson, 2003; Roth, 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infection, severe (in combination with metronidazole):</b> IV: 2 g every 8  hours for 4 to 7 days (provided source controlled). Not recommended for hospital-acquired intra-abdominal infections (IAI) associated with multidrug-resistant gram negative organisms or in mild-to-moderate community-acquired IAIs due to risk of toxicity and the development of resistant organisms (Solomkin, 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Melioidosis (off-label use): IV: Note:</b> Switching to meropenem therapy is indicated if patient condition worsens (eg, organ failure, new infection focus development, repeat blood cultures remained positive). Oral eradication therapy is recommended after the intensive (acute) phase treatment is complete (Lipsitz, 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Severe, acute phase:</i> 50 mg/kg/dose every 8 hours (maximum dose: 2 g) or 2 g for one dose, followed by 6 g daily by continuous infusion for &ge;10 days with or without TMP/SMX (Lipsitz, 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-cystic fibrosis bronchiectasis (off-label use/route):</b> Inhalation for nebulization: 250 to 1,000 mg every 12 hours or 500 mg every 6 hours for up to 12 months (Le 2010, Orriols 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteomyelitis, native vertebral due to </b>\n      <b>P. aeruginosa </b>\n      <b>(alternative therapy)</b> <b>(off-label dose): </b>IV: 2 g every 8 hours for 6 weeks <b>Note: </b>Double coverage may be considered (ie, ceftazidime plus an aminoglycoside or ciprofloxacin) (IDSA [Berbari 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peritonitis (CAPD) (off-label route; Li, 2010):</b> Intraperitoneal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intermittent:</i> 1 to 1.5 g every 24 hours per exchange in the long dwell (&ge;6 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Continuous (per liter exchange):</i> Loading dose: 500 mg; maintenance dose: 125 mg. <b>Note:</b> If patient has residual renal function (eg, &gt;100 mL/day urine output), empirically increase each dose by 25%.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Uncomplicated:</i> IM, IV: 500 mg to 1 g every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hospital-acquired or ventilator-associated (off-label):</i> IV: 2 g every 8 hours for 7 days; may consider shorter or longer duration depending on rate of clinical improvement. When used as empiric therapy, use in combination with an agent active against <i>S. aureus</i> with or without an additional antipseudomonal agent (dependent on patient and institution-specific risk factors) (Kalil 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prosthetic joint infection,</b> <b><i>Pseudomonas aeruginosa</i></b> <b>(alternative to cefepime or meropenem):</b> IV: 2 g every 8 hours for 4 to 6 weeks (consider addition of an aminoglycoside) (Osmon, 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and soft tissue infections:</b> IV, IM: 500 mg to 1 g every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Severe infections, including meningitis, CNS infection, osteomyelitis, gynecological:</b> IV: 2 g every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infections:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer&rsquo;s labeling:</i> IV, IM:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Uncomplicated: 250 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Complicated: 500 mg every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i> Alternative recommendations: </i>IV: Complicated: 1 to 2 g every 8 to 12 hours (Hoepelman 1993; Norrby 1992).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147959\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=ceftazidime-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ceftazidime: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infections:</b> IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling: </i>Infants and Children: 30 to 50 mg/kg/dose every 8 hours; maximum daily dose: 6 g/<b>day</b>; higher doses reserved for immunocompromised patients, cystic fibrosis, or meningitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing (Red Book [AAP 2015])</i>: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate infections: 90 to 150 mg/kg/day divided every 8 hours; maximum daily dose: 3,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe infections: 200 mg/kg/day divided every 8 hours; maximum daily dose: 6 g/<b>day</b>; higher doses (300 mg/kg/<b>day</b>) have been recommended for cystic fibrosis patients</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Catheter-related blood stream infections (off-label use):</b> Infants and Children &le;12 years: IV: 100 to 150 mg/kg/day in divided doses every 8 hours for 7 to 14 days (Maximum daily dose: 6 g daily) (Mermel 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystic fibrosis, lung infection caused by <b><i>Pseudomonas</i></b> spp:</b> Infants, Children, and Adolescents: IV: 150 to 200 mg/kg/day divided every 6 to 8 hours, maximum daily dose: 6 g/<b>day</b>; higher doses have been used: 200 to 400 mg/kg/day divided every 6 to 8 hours; maximum daily dose: 12 g/<b>day</b> (Zobell 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, treatment (off-label use):</b> Children and Adolescents: IV: 100 to 150 mg/kg/<b>day</b> divided every 8 hours; maximum daily dose: 4,000 mg/<b>day</b>; use in combination with gentamicin or vancomycin/gentamicin (add rifampin if prosthetic material is present) depending on the cause of infection (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Melioidosis (off-label use): Note:</b> Switching to meropenem therapy is indicated if patient condition worsens (eg, organ failure, new infection focus development, repeat blood cultures remained positive). Oral eradication therapy is recommended after the intensive (acute) phase treatment is complete (Lipsitz 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Severe, acute phase: </i> Infants &ge;3 months, Children, and Adolescents: IV: 50 mg/kg/dose every 8 hours for &ge;10 days with or without TMP/SMX (maximum dose: 2,000 mg/dose) (Lipsitz 2012). <b>Note:</b> Depending on infection severity, the dose for patients &ge;3 months can be &le;40 mg/kg (maximum dose: 2,000 mg/dose) (Lipsitz 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147938\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147939\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> If the dose recommended in the dosing section is lower than that recommended for patients with renal insufficiency as outlined below, the lower dose should be used. In severe infections, when the usual dose would be ceftazidime 6 g/day in patients without renal impairment, consider increasing the doses below by 50% or increase the dosing frequency. Further dosage adjustments should be determined by infection severity, susceptibility and patient response to therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 31 to 50 mL/minute: 1 g every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 16 to 30 mL/minute: 1 g every 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 6 to 15 mL/minute: 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &lt;5 mL/minute: 500 mg every 48 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Dialyzable (50% to 100%): 500 mg to 1 g every 24 hours <b>or</b> 1 to 2 g every 48 to 72 hours (Heintz, 2009). <b>Note:</b> Dosing dependent on the assumption of  3 times per week, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Peritoneal dialysis (PD): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent: Loading dose of 1 g, followed by 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous: Loading dose of 1 g, followed by 500 mg every 24 hours. <b>Note:</b> an additional 125 mg per liter of exchange fluid may be added to the dialysate if clinically warranted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005):  Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CVVH: Loading dose of 2 g followed by 1 to 2 g every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CVVHD/CVVHDF: Loading dose of 2 g followed by either 1 g every 8 hours <b>or</b> 2 g every 12 hours. <b>Note:</b> Dosage of 1 g every 8 hours results in similar steady-state concentrations as 2 g every 12 hours and is more cost effective. Dosage of 2 g every 8 hours may be needed for gram-negative rods with MIC &ge;4 mg/L (Heintz, 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <b>Note:</b> For patients receiving CVVHDF, some recommend giving a loading dose of 2 g followed by 3 g over 24 hours as a continuous IV infusion to maintain concentrations &ge;4 times the MIC for susceptible pathogens (Heintz, 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682549\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147911\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sodium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fortaz in D5W: 1 g (50 mL); 2 g (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tazicef: 1 g/50 mL (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fortaz: 500 mg (1 ea); 1 g (1 ea); 2 g (1 ea); 6 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tazicef: 1 g (1 ea); 2 g (1 ea); 6 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea); 6 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea); 6 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fortaz: 1 g (1 ea); 2 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tazicef: 1 g (1 ea); 2 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g/50 mL (1 ea); 2 g/50 mL (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147895\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147915\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Ceftazidime can be administered deep IM into large mass muscle.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Can be administered IVP over 3 to 5 minutes, or by IV intermittent infusion over 15 to 30 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intravitreal: Ceftazidime may be administered intravitreally as 2 to 2.25 mg/0.1 mL NS in combination with vancomycin (separate syringes) (Jackson 2003; Roth 1997).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intraperitoneal: Intraperitoneal administration may be used <b>in conjunction with</b> IV use for systemic infections if continuous peritoneal dialysis is used (added to the dialysate in each exchange). Intraperitoneal administration alone may also be used for the treatment of peritonitis and added to the dialysate in intermittent (added to the longest dwell time per day) or continuous (loading dose, followed by a maintenance dose per liter of exchange) peritoneal dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalation for nebulization (off-label use/route): Use with standard jet nebulizer connected to an air compressor; administer 1,000 mg diluted in 8 mL NS with mouthpiece or face mask (Orriols 1999).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147914\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacterial septicemia:</b> Treatment of septicemia caused by <i>Pseudomonas aeruginosa</i>, <i>Klebsiella</i> spp., <i>Haemophilus influenzae</i>, <i>Escherichia coli</i>, <i>Serratia</i> spp., <i>Streptococcus pneumoniae</i>, and <i>Staphylococcus aureus</i> (methicillin-susceptible strains).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bone and joint infections:</b> Treatment of bone and joint infections caused by <i>Pseudomonas aeruginosa</i>, <i>Klebsiella</i> spp., <i>Enterobacter</i> spp., and <i>Staphylococcus aureus</i> (methicillin-susceptible strains).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CNS infections:</b> Treatment of meningitis caused by <i>Haemophilus influenzae</i> and <i>Neisseria meningitidis</i>. Ceftazidime has also been used successfully in cases of meningitis due to <i>Pseudomonas aeruginosa</i> and <i>Streptococcus pneumoniae</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Empiric therapy in the immunocompromised patient:</b>  Empiric treatment of infections in immunocompromised patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gynecologic infections:</b> Treatment of endometritis, pelvic cellulitis, and other infections of the female genital tract caused by <i>Escherichia coli</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infections:</b> Treatment of peritonitis caused by <i>Escherichia coli</i>, <i>Klebsiella</i> spp., and <i>Staphylococcus aureus</i> (methicillin-susceptible strains) and polymicrobial intra-abdominal infections caused by aerobic and anaerobic organisms and some <i>Bacteroides</i> spp. (many strains of <i>Bacteroides fragilis</i> are resistant).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lower respiratory tract infections:</b> Treatment of lower respiratory tract infections, including pneumonia, caused by <i>Pseudomonas aeruginosa</i> and other <i>Pseudomonas</i> spp.; <i>Haemophilus influenzae</i>, including ampicillin-resistant strains; <i>Klebsiella</i> spp.; <i>Enterobacter</i> spp.; <i>Proteus mirabilis</i>; <i>Escherichia coli</i>; <i>Serratia</i> spp.; <i>Citrobacter</i> spp.; <i>Streptococcus pneumoniae</i>; and <i>Staphylococcus aureus</i> (methicillin-susceptible strains).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin-structure infections:</b> Treatment of skin and skin-structure infections caused by <i>Pseudomonas aeruginosa</i>; <i>Klebsiella</i> spp.; <i>Escherichia coli</i>; <i>Proteus</i> spp.; including <i>Proteus mirabilis</i> and indole-positive <i>Proteus</i>; <i>Enterobacter</i> spp.; <i>Serratia</i> spp.; <i>Staphylococcus aureus</i> (methicillin-susceptible strains); and <i>Streptococcus pyogenes</i> (group A beta-hemolytic streptococci).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infections (UTI):</b> Treatment of complicated and uncomplicated UTIs caused by <i>Pseudomonas aeruginosa</i>; <i>Enterobacter</i> spp.; <i>Proteus</i> spp., including <i>Proteus mirabilis</i> and indole-positive <i>Proteus</i>; <i>Klebsiella</i> spp.; and <i>Escherichia coli</i>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475339\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Bacterial endophthalmitis; Catheter-related bloodstream infections (children/adolescents); Endocarditis, treatment (children); Melioidosis (Burkholderia pseudomallei) infection; Non&ndash;cystic fibrosis bronchiectasis (aerosolized ceftazidime)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147987\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CefTAZidime may be confused with ceFAZolin, cefepime, cefoTEtan, cefOXitin,  cefTRIAXone</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ceptaz may be confused with Septra</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tazicef may be confused with Tazidime</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ceftim [Portugal] and Ceftime [Thailand] brand names for ceftazidime may be confused with Ceftin brand name for cefuroxime [U.S., Canada]; Cefiton brand name for cefixime [Portugal]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147902\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (&lt;2%), skin rash (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased lactate dehydrogenase (6%), increased gamma-glutamyl transferase (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Eosinophilia (8%), positive direct Coombs test (4%; without hemolysis), thrombocythemia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (7%), increased serum AST (6%), increased serum alkaline phosphatase (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reactions (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Inflammation at injection site (1%), injection site phlebitis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Seizure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Agranulocytosis, leukopenia, lymphocytosis, neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased blood urea nitrogen, increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, anaphylaxis (severe in rare instances, including cardiopulmonary arrest), angioedema, candidiasis, <i>Clostridium difficile</i> associated diarrhea, dizziness, erythema multiforme, headache, hemolytic anemia, hyperbilirubinemia, jaundice, nausea, pain at injection site, paresthesia, renal insufficiency, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria, vaginitis, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147918\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Clinically significant hypersensitivity to ceftazidime, other cephalosporins, penicillins, other beta-lactam antibiotics, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147899\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elevated INR: May be associated with increased INR, especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurotoxicity: High ceftazidime levels in patients with renal insufficiency can lead to seizures, encephalopathy, coma, asterixis, myoclonia, and neuromuscular excitability. Reduce total daily dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298996\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147904\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9226&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Systemic): May diminish the therapeutic effect of CefTAZidime. Management: Consider using a different combination of antimicrobials, especially if bactericidal activity is desired. If these agents are combined, monitor for reduced antimicrobial effectiveness and/or therapeutic failure.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147907\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5951787\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Ceftazidime crosses the placenta and reaches the cord serum and amniotic fluid. An increase in most types of birth defects was not found following first trimester exposure to cephalosporins. Maternal peak serum concentration is unchanged in the first trimester. After the first trimester, serum concentrations decrease by approximately 50% of those in nonpregnant patients. Renal clearance is increased during pregnancy. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147921\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Very small amounts of ceftazidime are excreted in breast milk. The manufacturer recommends that caution be exercised when administering ceftazidime to nursing women. Ceftazidime in not absorbed when given orally; therefore, any medication that is distributed to human milk should not result in systemic concentrations in the nursing infant. Nondose-related effects could include modification of bowel flora.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147922\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147909\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor renal function. Observe for signs and symptoms of anaphylaxis during first dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147898\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs), which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147917\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely throughout the body including bone, bile, skin, CSF (higher concentrations achieved when meninges are inflamed), endometrium, heart, pleural and lymphatic fluids </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &lt;10% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 1 to 2 hours, prolonged with renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IM: ~1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (80% to 90% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323051\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Tazicef Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 gm/50 mL (50 mL): $16.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CefTAZidime and Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 gm/50 mL (1): $12.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 gm/50 mL (1): $17.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CefTAZidime Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $6.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $13.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 g (1): $35.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Tazicef Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $5.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $11.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 g (1): $36.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Tazicef Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $6.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $13.07</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147923\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Baxidyme (PH);</li>\n      <li>Biotum (PL, UA);</li>\n      <li>Biozim (ID);</li>\n      <li>Caltum (ID);</li>\n      <li>Cef-H (MY);</li>\n      <li>Cefa 3 (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Cefadime (TW);</li>\n      <li>Cefatum (MY);</li>\n      <li>Cefaz (HR);</li>\n      <li>Cefazime (SG);</li>\n      <li>Cefdim (ID);</li>\n      <li>Cefortam (PT);</li>\n      <li>Cefpiran (PE);</li>\n      <li>Cefranz (PH);</li>\n      <li>Ceftamil (RO);</li>\n      <li>Ceftaz (LK);</li>\n      <li>Ceftazash (ET);</li>\n      <li>Ceftazivit (VN);</li>\n      <li>Ceftidin (IN);</li>\n      <li>Ceftim (IT, PT);</li>\n      <li>Ceftum (ID, JO);</li>\n      <li>Celodim (ID);</li>\n      <li>Cestazid (PH);</li>\n      <li>Cetazine (TW);</li>\n      <li>Cetazum (ID);</li>\n      <li>Cezidin (MT);</li>\n      <li>Dimcef (KR);</li>\n      <li>Dimzef (PH);</li>\n      <li>Elzid (LK);</li>\n      <li>Extimon (ID);</li>\n      <li>Fivtum (PH);</li>\n      <li>Fortam (CH, ES, UY);</li>\n      <li>Fortaz (BR);</li>\n      <li>Fortum (AE, AR, AT, AU, BB, BF, BG, BH, BJ, BM, BS, BZ, CI, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ET, FR, GB, GH, GM, GN, GT, GY, HK, HN, HU, ID, IE, IL, IN, IQ, IR, IS, JM, JO, KE, KR, KW, LB, LK, LR, LT, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PH, PR, PY, QA, RO, RU, SA, SC, SD, SE, SI, SK, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UG, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Fortum Pro (HN);</li>\n      <li>Fortumset (FR);</li>\n      <li>Forzid (PH);</li>\n      <li>Ftazidime (GR);</li>\n      <li>Glazidim (BE, FI, IT, LU);</li>\n      <li>Izadima (DO, EC, GT, HN, NI, PA, SV);</li>\n      <li>Kabi (UA);</li>\n      <li>Kefadim (BF, BJ, CI, ET, GH, GM, GN, KE, LR, LU, MA, ML, MR, MU, MW, NE, NG, PK, SC, SD, SL, SN, TN, TW, TZ, UG, VN, ZA, ZM, ZW);</li>\n      <li>Kefazim (AT);</li>\n      <li>Kefzim (CL);</li>\n      <li>Lacedim (ID);</li>\n      <li>Lemoxol (NZ);</li>\n      <li>Maxidim (BD);</li>\n      <li>Megacef (PH);</li>\n      <li>Mirocef (HR);</li>\n      <li>Negacef (AE, BH, KW, LB, QA, SA);</li>\n      <li>Orzid (ET);</li>\n      <li>Pharodime (ID);</li>\n      <li>Romacef (PH);</li>\n      <li>Septax (IL);</li>\n      <li>Solvetan (GR);</li>\n      <li>Spectrum (IT);</li>\n      <li>Starcef (IT);</li>\n      <li>Tagal (MX);</li>\n      <li>Tazicef (KR, PH);</li>\n      <li>Tazidan (PH);</li>\n      <li>Tazidem (PH);</li>\n      <li>Tazime (CN, KR, SG);</li>\n      <li>Thidim (ID);</li>\n      <li>Tinacef (AR, PY);</li>\n      <li>Trizidim (BD);</li>\n      <li>Trofiz (UA);</li>\n      <li>UIzadima (CR);</li>\n      <li>Yadim (HK);</li>\n      <li>Zadolina (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Zeptrigen (PH);</li>\n      <li>Zibac (ID);</li>\n      <li>Zidd (UA);</li>\n      <li>Zidimax (BD);</li>\n      <li>Zidime (AE, JO, KW, QA);</li>\n      <li>Zidmbiotic (VN);</li>\n      <li>Zitadim (ID);</li>\n      <li>Zitum (BD);</li>\n      <li>Zytaz (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515. doi: 10.1161/CIR.0000000000000298<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/26229122/pubmed\" target=\"_blank\" id=\"26229122\">26229122</a>]</span><span class=\"doi\">10.1093/cid/civ482</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cefpirome versus ceftazidime in the treatment of urinary tract infections. <i>J Antimicrob Chemother</i>. 1992;29(suppl A):95-104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/1601765/pubmed\" target=\"_blank\" id=\"1601765\">1601765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ceftazidime and Dextrose [prescribing information]. Bethlehem, PA: B. Braun Medical Inc; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davies SP, Lacey LF, Kox WJ, et al, &ldquo;Pharmacokinetics of Cefuroxime and Ceftazidime in Patients With Acute Renal Failure Treated by Continuous Arteriovenous Haemodialysis,&rdquo; <i>Nephrology, Dialysis, Transplantation</i>, 1991, 6(120):971-6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo; <i>N Engl J Med</i>, 1988, 318(7):419-26 and 318(8):490-500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/3277054/pubmed\" target=\"_blank\" id=\"3277054\">3277054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fortaz (ceftazidime) [prescribing information]. Cary, NC: Covis Pharmaceuticals; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fortaz (ceftazidime) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc.; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoepelman AI, Kieft H, Aoun M, Kosmidis J, Strand T, Verhoef J, Gillespie SH, Riddell J, Varghese G, Meunier F. International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections. <i>J Antimicrob Chemother</i>. 1993;32(suppl B):175-186.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/8150761/pubmed\" target=\"_blank\" id=\"8150761\">8150761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jackson TL, Eykyn SJ, Graham EM, Stanford MR. Endogenous bacterial endophthalmitis: a 17-year prospective series and review of 267 reported cases. <i>Surv Ophthalmol</i>. 2003;48(4):404-423.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/12850229/pubmed\" target=\"_blank\" id=\"12850229\">12850229</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society [published online July 14, 2016]. <i>Clin Infect Dis</i>. doi: 10.1093/cid/ciw353.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/27418577/pubmed\" target=\"_blank\" id=\"27418577\">27418577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7487614\"></a>Kelsey SF, David M, Doft BH, et al, &ldquo;Results of the Endophthalmitis Vitrectomy Study. A Randomized Trial of Immediate Vitrectomy and of Intravenous Antibiotics for the Treatment of Postoperative Bacterial Endophthalmitis. Endophthalmitis Vitrectomy Study Group,&rdquo; <i>Arch Ophthalmol</i>, 1995, 113(12):1479-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/7487614/pubmed\" target=\"_blank\" id=\"7487614\">7487614</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klein NC and Cunha BA, &ldquo;Third-Generation Cephalosporins,&rdquo; <i>Med Clin North Am</i>, 1995, 79(4):705-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/7791418/pubmed\" target=\"_blank\" id=\"7791418\">7791418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Le J, Ashley ED, Neuhauser MM, et al; Society of Infectious Diseases Pharmacists Aerosolized Antimicrobials Task Force. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i>. 2010;30(6):562-584.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/20500046/pubmed\" target=\"_blank\" id=\"20500046\">20500046</a>]</span><span class=\"doi\">10.1592/phco.30.6.562</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li PK, Szeto CC, Piraino B, et al; International Society for Peritoneal Dialysis. Peritoneal dialysis-related infections recommendations: 2010 update [published correction appears in <i>Perit Dial Int</i>. 2011;31(5):512]. <i>Perit Dial Int</i>. 2010;30(4):393-423.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/20628102/pubmed\" target=\"_blank\" id=\"20628102\">20628102</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23171644\"></a>Lipsitz R, Garges S, Aurigemma R, et al. Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei infection, 2010. <i>Emerg Infect Dis</i>. 2012;18(12):e2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/23171644/pubmed\" target=\"_blank\" id=\"23171644\">23171644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Berendt AR, Cornia PB, et al, &quot;2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,&quot; <i>Clin Infect Dis</i>, 2012, 54(12):e132-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/22619242/pubmed\" target=\"_blank\" id=\"22619242\">22619242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marshall WF and Blair JE, &ldquo;The Cephalosporins,&rdquo; <i>Mayo Clin Proc</i>, 1999, 74(2):187-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/10069359/pubmed\" target=\"_blank\" id=\"10069359\">10069359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCracken GH Jr, Threlkeld N, and Thomas ML, &ldquo;Pharmacokinetics of Ceftazidime in Newborn Infants,&rdquo; <i>Antimicrob Agents Chemother</i>, 1984, 26(4):583-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/6393862/pubmed\" target=\"_blank\" id=\"6393862\">6393862</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America [published corrections appear in <i>Clin Infect Dis</i>. 2010;50(7):1079 and <i>Clin Infect Dis</i>. 2010;50(3):457]. <i>Clin Infect Dis</i>. 2009;49(1):1-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/19489710/pubmed\" target=\"_blank\" id=\"19489710\">19489710</a>]</span><span class=\"doi\">10.1086/599376</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Orriols R, Roig J, Ferrer J, et al. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. <i>Respir Med</i>. 1999;93(7):476-480.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/10464834/pubmed\" target=\"_blank\" id=\"10464834\">10464834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pickering LK, ed. <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rains CP, Bryson HM, and Peters DH, &ldquo;Ceftazidime. An Update of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Efficacy,&rdquo; <i>Drugs</i>, 1995, 49(4):577-617.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/7789291/pubmed\" target=\"_blank\" id=\"7789291\">7789291</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson DG, Cookson TL, and Frisafe JA, &ldquo;Concentration Guidelines for Parenteral Antibiotics in Fluid-Restricted Patients,&rdquo; <i>Drug Intell Clin Pharm</i>, 1987, 21(12):985-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/3428165/pubmed\" target=\"_blank\" id=\"3428165\">3428165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roth DB and Flynn HW Jr, &ldquo;Antibiotic Selection in the Treatment of Endophthalmitis: The Significance of Drug Combinations and Synergy,&rdquo; <i>Surv Ophthalmol</i>, 1997, 41(5):395-401.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/9163836/pubmed\" target=\"_blank\" id=\"9163836\">9163836</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sirgo MA and Norris S, &ldquo;Ceftazidime in the Elderly: Appropriateness of Twice-Daily Dosing,&rdquo; <i>DICP Ann Pharmacother</i>, 1991, 25(3):284-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Slaker RA and Danielson B, &ldquo;Neurotoxicity Associated With Ceftazidime Therapy in Geriatric Patients With Renal Dysfunction,&rdquo; <i>Pharmacotherapy</i>, 1991, 11(4):351-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/1923920/pubmed\" target=\"_blank\" id=\"1923920\">1923920</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stea S, Bachelor T, Cooper M, et al, &ldquo;Disposition and Bioavailability of Ceftazidime After Intraperitoneal Administration in Patients Receiving Continuous Ambulatory Peritoneal Dialysis,&rdquo; <i>J Am Soc Nephrol</i>, 1996, 7(11):2399-402.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/8959631/pubmed\" target=\"_blank\" id=\"8959631\">8959631</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tazicef (ceftazidime) [prescribing information]. Lake Forest, IL: Hospira; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vlasses PH, Bastion WA, Behal R, et al, &ldquo;Ceftazidime Dosing in the Elderly: Economic Implications,&rdquo; <i>Ann Pharmacother</i>, 1993, 27(7-8):967-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/8364284/pubmed\" target=\"_blank\" id=\"8364284\">8364284</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson W, Taubert KA, Gewitz M, et al, &ldquo;Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&rdquo; <i>Circulation</i>, 2007, 116(15):1736-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/17446442/pubmed\" target=\"_blank\" id=\"17446442\">17446442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zobell JT, Waters CD, Young DC, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins. <i>Pediatr Pulmonol</i>. 2013;48:107-122.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-drug-information/abstract-text/22949297/pubmed\" target=\"_blank\" id=\"22949297\">22949297</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9226 Version 192.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F147933\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F147934\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F147980\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F147937\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F147959\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F147938\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F147939\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15682549\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F147911\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F147895\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F147915\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F147914\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475339\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F147987\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F147902\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F147918\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F147899\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298996\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F147904\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F147907\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5951787\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F147921\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F147922\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F147909\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F147898\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F147917\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323051\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F147923\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9226|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ceftazidime-patient-drug-information\" class=\"drug drug_patient\">Ceftazidime: Patient drug information</a></li><li><a href=\"topic.htm?path=ceftazidime-pediatric-drug-information\" class=\"drug drug_pediatric\">Ceftazidime: Pediatric drug information</a></li></ul></div></div>","javascript":null}